Clinical Trial: Combination Therapy in Cancers With Mutations in DNA Repair Genes
Study Status: Completed
Recruit Status: RECRUITING
Condition: Metastatic Solid Tumor
Study Type: INTERVENTIONAL
Official Title: Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes
Brief Summary:
The purpose of this phase 1 clinical trials is to determine whether niraparib (a Poly (ADP-ribose) polymerase inhibitor (PARPi)) can be safely combined with irinotecan with manageable toxicity and reasonable efficacy.Emerging evidence suggest that PARPi is an effective therapeutic strategy in a wider subset of solid tumors that may have defective homologous recombination (HR) or DNA repair gene mutations.BReast CAncer gene (BRCA), partner and localizer of BRCA2 (PALB2), and various other DNA repair germline…
Read more